Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F140 - Acne Boot Camp

Monday, February 19; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Manage acne vulgaris effectively
  • Select new treatment options more effectively

Description

This session is directed to dermatologists who treat acne and will cover the basics of acne treatment as well as novel treatment options.

Disclosures

  • Bhatia, Neal D., MD: Aclaris Therapeutics, Inc. – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); Allergan, Inc – C(H); Almirall – C(H); Aqua – C(H); Asana Biosciences, LLC – I(Grants/Research Funding); Atacama Therapeutics – I(Grants/Research Funding); Bayer Pharmaceuticals – C(H); Biofrontera AG – C(H); BioPharmX – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Cipher Pharmaceuticals – C(H); Crown Laboratories, Inc. – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Ferndale Laboratories, Inc. – C(H); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H); Glenmark Generics Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – C(H); ISDIN – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); LEO Pharma, US – I(Grants/Research Funding); Mayne Pharma Group – C(H); MC2 Therapeutics – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Mylan Technologies Inc. – C(H); Novartis Pharmaceuticals Corp. – C(H); Ortho Dermatologics – C(H); Par Pharmaceutical – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – C(H); Promius Pharma, LLC – A(H); Realm Therapeutics – I(Grants/Research Funding); Sanofi/Regeneron – C(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – I(Grants/Research Funding); Skinfix, Inc. – A(H); Sol-Gel Technologies – I(Grants/Research Funding); Soligenix, Inc – I(Grants/Research Funding); Strata Skin Sciences – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); Valeant Pharmaceuticals International – C(H); Viamet Pharmaceuticals, Inc – I(Grants/Research Funding); Vidac Pharma – I(Grants/Research Funding); Vyome Biosciences – I(Grants/Research Funding);
  • Green, Lawrence J., MD: AbbVie – SP(H); Allergan, Inc. – C(H), Speaker/Faculty Education(H); Amgen – SP(H); Brickell Biotech, Inc. – I(Grants/Research Funding); Celgene Corporation – SP(H); Dermira – I(Grants/Research Funding); Leo Pharma Inc. – SP(H); Merz Aesthetics – A(H), I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding), SP(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding); ZO Skin Health, Inc. – C(H);
  • Harper, Julie Claire, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – SP(H); Aqua – C(H); Bayer Pharmaceuticals – I(Fees), O(H); BioPharmX – A(H); Dermira – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – SP(H); La Roche-Posay Laboratoire Pharmaceutique – SP(H); Novan – A(H); Promius Pharma, LLC – SP(H); Taro Pharm – A(H); Valeant Pharmaceuticals North America LLC – SP(H);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Zeichner, Joshua, MD: Allergan, Inc – A(H); Allergan, Inc. – Speaker/Faculty Education(H); Bayer Pharmaceuticals – Speaker/Faculty Education(H); Foamix – A(H); Galderma Laboratories, L.P. – C(H); Johnson & Johnson Consumer Products Company – C(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); Pfizer Inc. – A(H), Speaker/Faculty Education(H); Promius Pharma, LLC – A(H); Regeneron – Speaker/Faculty Education(H); Valeant Pharmaceuticals International – A(H);
Schedule
Monday, February 19
3:30 PM
Dr. Kircik and Dr. Zeichner / Introduction
3:35 PM
Dr. Bhatia / Oral Antibiotics for Acne
3:55 PM
Dr. Green / Topical Agents for Acne
4:15 PM
Dr. Zeichner / Isotretinoin for Acne
4:35 PM
Dr. Harper / Hormonal Therapies for Acne
4:55 PM
Dr. Kircik / New Therapies for Acne
5:15 PM
All faculty / Q&A
Event Details
  • Date
    Monday, February 19
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 28D
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Leon H. Kircik, MD, FAAD - Handout
  • Joshua Zeichner, MD, FAAD
Speakers